Figure S9. Investigation of sources of possible heterogeneity in reported associations of t-PA antigen, D-dimer and VWF with coronary heart disease risk, according to various study-level characteristics.

### Subgroup Analysis

#### t-PA antigen

**Study size**
- < 500 cases: 10 studies, 2591 cases, Relative risk: 1.15 (1.05, 1.27), P = 0.633
- ≥ 500 cases: 3 studies, 2903 cases, Relative risk: 1.10 (1.00, 1.21)

**Sex**
- Men: 5 studies, 2698 cases, Relative risk: 1.11 (1.02, 1.19), P = 0.847
- Women: 3 studies, 1056 cases, Relative risk: 1.15 (0.89, 1.47)

**Not reported separately**
- Duration of follow-up: 6 studies, 1740 cases, Relative risk: 1.16 (1.03, 1.30)
- < 10 years: 7 studies, 1799 cases, Relative risk: 1.10 (0.98, 1.23), P = 0.367
- ≥ 10 years: 6 studies, 3695 cases, Relative risk: 1.17 (1.07, 1.28)

**Sample source**
- Plasma: 10 studies, 2830 cases, Relative risk: 1.12 (1.03, 1.23), P = 0.656
- Serum: 3 studies, 2964 cases, Relative risk: 1.17 (1.02, 1.34)

**Storage temperature**
- > -70°C: 4 studies, 2912 cases, Relative risk: 1.20 (1.06, 1.36), P = 0.321
- ≤ -70°C: 9 studies, 2582 cases, Relative risk: 1.10 (1.01, 1.20)

**Fasting status**
- Fasted: 10 studies, 4463 cases, Relative risk: 1.11 (1.03, 1.21), P = 0.370
- Non-fasted: 3 studies, 1031 cases, Relative risk: 1.22 (1.10, 1.35)

**Total**
- 13 studies, 5494 cases, Relative risk: 1.13 (1.06, 1.21)

#### D-dimer

**Study size**
- < 500 cases: 15 studies, 3871 cases, Relative risk: 1.25 (1.17, 1.32), P = 0.375
- ≥ 500 cases: 3 studies, 2928 cases, Relative risk: 1.18 (1.03, 1.34)

**Sex**
- Men: 8 studies, 3593 cases, Relative risk: 1.18 (1.10, 1.27), P = 0.341
- Women: 3 studies, 1135 cases, Relative risk: 1.17 (1.07, 1.40)

**Not reported separately**
- Duration of follow-up: 8 studies, 2071 cases, Relative risk: 1.32 (1.17, 1.49)
- < 10 years: 13 studies, 3228 cases, Relative risk: 1.25 (1.15, 1.35), P = 0.615
- ≥ 10 years: 5 studies, 3571 cases, Relative risk: 1.21 (1.05, 1.35)

**Sample source**
- Plasma: 16 studies, 4244 cases, Relative risk: 1.25 (1.17, 1.33), P = 0.387
- Serum: 2 studies, 2555 cases, Relative risk: 1.17 (0.96, 1.43)

**Storage temperature**
- > -70°C: 4 studies, 2968 cases, Relative risk: 1.15 (1.02, 1.30), P = 0.163
- ≤ -70°C: 14 studies, 3831 cases, Relative risk: 1.26 (1.18, 1.35)

**Fasting status**
- Fasted: 14 studies, 5518 cases, Relative risk: 1.23 (1.14, 1.32), P = 0.823
- Non-fasted: 4 studies, 1281 cases, Relative risk: 1.26 (1.05, 1.50)

**Total**
- 18 studies, 6799 cases, Relative risk: 1.23 (1.16, 1.32)

#### VWF

**Study size**
- < 500 cases: 11 studies, 2900 cases, Relative risk: 1.16 (1.08, 1.26), P = 0.979
- ≥ 500 cases: 4 studies, 3656 cases, Relative risk: 1.16 (1.07, 1.25)

**Sex**
- Men: 6 studies, 2732 cases, Relative risk: 1.16 (1.07, 1.25), P = 0.219
- Women: 3 studies, 1135 cases, Relative risk: 1.05 (0.92, 1.19)

**Not reported separately**
- Duration of follow-up: 7 studies, 2989 cases, Relative risk: 1.20 (1.11, 1.29)
- < 10 years: 8 studies, 2152 cases, Relative risk: 1.12 (1.06, 1.19), P = 0.344
- ≥ 10 years: 7 studies, 4404 cases, Relative risk: 1.19 (1.10, 1.30)

**Sample source**
- Plasma: 12 studies, 3922 cases, Relative risk: 1.15 (1.09, 1.23), P = 0.808
- Serum: 3 studies, 2634 cases, Relative risk: 1.18 (1.02, 1.37)

**Storage temperature**
- > -70°C: 3 studies, 2798 cases, Relative risk: 1.19 (1.04, 1.37), P = 0.650
- ≤ -70°C: 12 studies, 3758 cases, Relative risk: 1.15 (1.08, 1.22)

**Fasting status**
- Fasted: 13 studies, 5737 cases, Relative risk: 1.14 (1.08, 1.20), P = 0.171
- Non-fasted: 2 studies, 819 cases, Relative risk: 1.30 (1.17, 1.45)

**Total**
- 15 studies, 6556 cases, Relative risk: 1.16 (1.10, 1.22)

Summary estimates were calculated using random effects models. *P values are from meta-regression for differences in odds ratios across studies in different groups.